Analyst Rating: Will Lucira Health Inc (LHDX) Stock Outperform the Market?

Wednesday, March 01, 2023 10:47 AM | InvestorsObserver Analysts

Mentioned in this article

Analyst Rating: Will Lucira Health Inc (LHDX) Stock Outperform the Market?

Wall Street is positive on Lucira Health Inc (LHDX). On average, analysts give LHDX a Buy rating. The average price target is $2.25, which means analysts expect the stock to gain by 77.17% over the next twelve months. That average ranking earns LHDX an Analyst Rating of 21, which is better than 21% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating LHDX a Buy today. Find out what this means to you and get the rest of the rankings on LHDX!

See Full LHDX Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Lucira Health Inc Stock Today?

Lucira Health Inc (LHDX) stock is up 36.56% while the S&P 500 has fallen -0.15% as of 10:43 AM on Wednesday, Mar 1. LHDX is higher by $0.34 from the previous closing price of $0.93 on volume of 83,371,475 shares. Over the past year the S&P 500 has fallen -7.94% while LHDX has fallen -72.86%. LHDX lost -$3.59 per share the over the last 12 months. Click Here to get the full Stock Report for Lucira Health Inc stock.